Astellas Eyes Doubling Market Cap On Core, Focus Assets

Offsetting Xtandi Patent Cliff

Astellas lays out new mid-term strategic plan it sees as overcoming looming major expiries while positioning the firm for growth in new areas and a more than doubling in market cap.

midtermplan
Astellas Lays Out New Mid-Term Targets • Source: Alamy

Astellas Pharma, Inc. is looking to Xtandi and a group of other core products to generate a combined $11bn or so in sales over the next few years under a new mid-term strategic plan which envisages the Japanese firm’s market capitalization more than doubling to nearly $64bn over the next five years.

The Corporate Strategic Plan 2021, laid out by president and CEO Kenji Yasukawa and running through to the end of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.